REFERENCES

Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Ingenol Mebutate (Picato): Topical Treatment of Non-hyperkeratotic, Non-hypertrophic Actinic Keratosis in Adults [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Feb.

Ingenol Mebutate (Picato): Topical Treatment of Non-hyperkeratotic, Non-hypertrophic Actinic Keratosis in Adults [Internet].

Show details

Contents

< Prev Next >

REFERENCES

1.: Pharmacoeconomic evaluation. In: CDR submission binder: Picato^® (ingenol mebutate) topical gel 0.015% and 0.05% [CONFIDENTIAL manufacturer's submission]. Thornhill (ON): LEO Pharma Inc; May, 2013.
2.: Clinical study report PEP005-016: A multi-center, randomized, parallel group, double-blind, vehicle-controlled study to evaluate the efficacy and safety of PEP005 (ingenol mebutate) gel, 0.015% in patients with actinic keratoses on the head (face or scalp) (REGION-IIa) [CONFIDENTIAL internal manufacturer's report]. Bowen Hills, QLD (Australia): Peplin Operations Pty Ltd; Sep 8, 2010.
3.: Clinical study report PEP005-025: A multi-center, randomized, parallel-group, double-blind, vehicle controlled study to evaluate the efficacy and safety of PEP005 (ingenol mebutate) gel, 0.015% in patients with actinic keratoses on the head (face or scalp) (REGION-IIb) [CONFIDENTIAL internal manufacturer's report]. Bowen Hills, QLD (Australia): Peplin Operations Pty Ltd; Sep 8, 2010.
4.: Clinical study report PEP005-014: A multi-center, randomized, parallel group, double-blind, vehicle-controlled study to evaluate the efficacy and safety of PEP005 (ingenol mebutate) gel, 0.05% in patients with actinic keratoses on non-head locations (REGION-I) [CONFIDENTIAL internal manufacturer's report]. Bowen Hills, QLD (Australia): Peplin Operations Pty Ltd; Sep 16, 2010.
5.: Clinical study report PEP005-028: A multi-center, randomized, parallel group, double-blind, vehicle-controlled study to evaluate the efficacy and safety of PEP005 (ingenol mebutate) gel, 0.05% in patients with actinic keratoses on non-head locations (REGIONIb) [CONFIDENTIAL internal manufacturer's report]. Bowen Hills, QLD (Australia): Peplin Operations Pty Ltd; Sep 8, 2010.
6.: Gupta AK, Paquet M, Villanueva E, Brintnell W. Interventions for actinic keratoses. Cochrane Database Syst Rev. 2012;12:CD004415. [PMC free article: PMC6599879] [PubMed: 23235610]
7.: Australian Government. Department of Health and Ageing. Ingenol, gel, 0.15 mg per g (0.015%), 70 mcg ingenol mebutate in 0.47 g single use tubes, 3, Picato^® [Internet]. Canberra: Commonwealth of Australia; 2012. [cited 2013 Jul 18]. Available from: http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2012-11/ingenol.
8.: National Institute for Health and Care Excellence. ESNM14: actinic keratosis: ingenol lmebutate gel [Internet]. London: The Institute; 2013. [cited 2013 Jul 18]. Available from: http://publications.nice.org.uk/esnm14-actinic-keratosis-ingenol-mebutate-gel-esnm14/relevance-to-nice-guidance-programmes.
9.: Scottish Medicines Consortium. Ingenol mebutate, 150 & 500 micrograms/g, gel Picato^®. LEO Laboratories. SMC no. (851/13) [Internet]. Glasgow: NHS Scotland; Mar 11, 2013. [cited 2013 Jul 29]. Available from: http://www.scottishmedicines.org.uk/files/advice/ingenol_mebutate_gel_Picato_FINAL_FEBRUARY_2013_amended_04.03.13_for_website.pdf.

You are permitted to make copies of this document for non-commercial purposes, provided it is not modified when reproduced and appropriate credit is given to CADTH. You may not otherwise copy, modify, translate, post on a website, store electronically, republish, or redistribute any material from this document in any form or by any means without the prior written permission of CADTH.

Please contact CADTH’s Vice-President of Corporate Services at ac.htdac@secivresetaroproc with any inquiries about this notice or other legal matters relating to CADTH’s services.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK195588

Contents

< Prev Next >

PubReader
Print View
Cite this Page
Ingenol Mebutate (Picato): Topical Treatment of Non-hyperkeratotic, Non-hypertrophic Actinic Keratosis in Adults [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Feb. REFERENCES.